A 28-year-old nulliparous woman is diagnosed with uterine leiomyomas (fibroids) causing menorrhagia and pelvic pain. She wishes to preserve fertility and avoid surgery. Which pharmacological agent is the first-line medical treatment to reduce fibroid volume and control bleeding?

Explanation

## Uterine Leiomyomas: Medical Management with GnRH Agonists **Key Point:** Leuprolide (a GnRH agonist) is the first-line pharmacological agent for reducing fibroid volume in women seeking fertility preservation. It induces a hypogonadal state, leading to fibroid shrinkage and symptom relief. ### Mechanism of Action Leuprolide suppresses gonadotropin-releasing hormone (GnRH) signaling, resulting in: - Downregulation of GnRH receptors on pituitary gonadotroph cells - Suppression of FSH and LH secretion - Marked reduction in circulating estrogen and progesterone - Fibroid involution (20–50% volume reduction within 3 months) - Reduced menstrual bleeding and pelvic pain ### Medical Agents for Uterine Leiomyomas: Comparison | Agent | Class | Fibroid Volume Reduction | Fertility Preservation | Onset | Limitations | |---|---|---|---|---|---| | **Leuprolide** | GnRH agonist | **20–50%** | Yes (reversible) | 2–4 weeks | Hypogonadal side effects; max 6 months | | Mifepristone | Progesterone antagonist | 20–30% | Yes | 4–8 weeks | Limited availability; off-label use | | Danazol | Androgen | 20–40% | No (teratogenic) | 2–4 weeks | Virilization, hepatotoxicity; contraindicated in pregnancy | | Norethindrone acetate | Progestin | Minimal | Yes | 1–2 weeks | Minimal volume reduction; symptom relief only | **High-Yield:** GnRH agonists are the **gold standard for preoperative fibroid shrinkage** and symptom control in women desiring fertility preservation. ### Clinical Pearl - **Preoperative use:** Leuprolide shrinks fibroids 2–4 weeks before myomectomy, reducing blood loss and operative time - **Reversibility:** Fertility returns within 1–2 menstrual cycles after discontinuation - **Duration:** Typically used for 3–6 months maximum (due to hypogonadal side effects: hot flashes, vaginal dryness, bone loss) - **Add-back therapy:** Low-dose estrogen–progestin or progestin alone can be co-prescribed to mitigate hypogonadal symptoms while preserving fibroid shrinkage ### Why Leuprolide Over Alternatives 1. **Mifepristone:** Progesterone antagonist with modest efficacy; not FDA-approved for fibroids in most countries; off-label use limits first-line status 2. **Danazol:** Androgenic side effects (virilization, clitoromegaly) and hepatotoxicity make it unacceptable in young women; teratogenic if pregnancy occurs 3. **Norethindrone acetate:** Progestin-only agent provides symptom relief but minimal fibroid shrinkage; does not address the underlying pathophysiology **Warning:** Do not confuse medical management (shrinkage) with symptomatic management (bleeding control). Norethindrone provides bleeding control but NOT fibroid reduction. [cite:Robbins 10e Ch 22]